Patients with HER2-positive metastatic breast cancer may consider related side effects and quality of life outcomes when choosing treatments.

In presenting Dr Slamon with the Ulysses Medal, UCD recognises that his pursuit of novel therapies for breast cancer for over ...

Per Genentech, the current price of Herceptin for a patient with “HER2 positive metastatic breast cancer” as about $50,000, a ...

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.